Gold tier: mechanically validated evidence, with its primary source.
682 evidence items · page 15 / 28
257 patientsA total of 257 patients with sickle cell anaemia (HbSS) were enrolled during the study period from January 2013 to April 2018.
Nigeriadrépanocytoseobserved January 2013 to April 2018published 2021Hematology/oncology and stem cell therapyPubMeddocument of 6 observations
3.4 mg/LThe mean beta-2-microglobulin (β2-M) among SCA patients was 3.4 ± 1.2 mg/L.
Nigeriadrépanocytosepublished 2023Malawi medical journal : the journal of Medical Association of MalawiPubMeddocument of 12 observations
10 monthsTime to significant decline in transcranial Doppler (TCD) velocities ranged from 5 to 35 months, with a median of 10.0 months.
Nigeriadrépanocytosepublished 2021Pediatric blood & cancerPubMeddocument of 5 observations
0.5 odds_ratio_per_1_g_HbThe odds of having abnormal LV geometry decreased by 0.5 for every 1 g increase in Hb level.
Nigeriadrépanocytosepublished 2026BMC cardiovascular disordersPubMeddocument of 6 observations
8.01 cmSickle cell anemia subjects had a smaller mean splenic size than non-SCA subjects (8.01 cm ± 1.89 vs. 8.19 cm ± 1.61).
Nigeriadrépanocytosepublished 2023Nigerian journal of clinical practicePubMeddocument of 9 observations
0.2 %Standard HemoTypeSC identified 1 (0.2%) HbAC phenotypes among 511 newborns.
Nigeriadrépanocytosepublished 2022Frontiers in geneticseurope_pmcdocument of 23 observations
1.2 %The combined prevalence of sickle cell disease genotypes (HbSS and HbSC) remained stable at approximately 1.2% among Nigerian university students between 2015 and 2024.
Nigeriadrépanocytoseobserved 2015-2024PubMeddocument of 3 observations
31.2 %Thirty-four (31.2%) children with sickle cell disease had low transferrin status.
Nigeriadrépanocytosepublished 2023West African journal of medicinePubMeddocument of 8 observations
17 %Among 164 mothers of children with SCD in a southwestern state of Nigeria, 28 (17%) were willing to partake in prenatal SCD diagnosis.
Nigeriadrépanocytosepublished 2020TheScientificWorldJournalPubMeddocument of 9 observations
8.91 cmLeft kidney length was significantly greater in sickle cell anemia patients (8.91 ± 1.16 cm vs. 8.27 ± 1.30 cm).
Nigeriadrépanocytosepublished 2023Nigerian journal of clinical practicePubMeddocument of 9 observations
54.5 umol/LThe median serum bilirubin level was 54.5 umol/L with an interquartile range of 37.0–119.0 umol/L.
Nigeriadrépanocytosepublished 2023West African journal of medicinePubMeddocument of 7 observations
76,711 NGNThe median monthly economic burden for sickle cell disease patients was approximately N76,711 (US$385) per person.
Nigeriadrépanocytosepublished 2022PloS onePubMeddocument of 5 observations
4 %The pooled prevalence of sickle cell disease among Nigerian children and adolescents was 4.0%.
Nigeriadrépanocytosepublished 2025Systematic reviewsPubMeddocument of 7 observations
0.8 %The prevalence of SCD among the infant cohort was 0.8%.
Nigeriadrépanocytosepublished 2020PloS onePubMeddocument of 4 observations
265.95 ng/mlThe median red cell folate level in children with sickle cell anaemia during crisis was 265.95 ng/ml.
Nigeriadrépanocytosepublished 2022Malawi medical journal : the journal of Medical Association of MalawiPubMeddocument of 3 observations
45.4 %Alpha thalassemia was present at a prevalence of 45.4% in sickle cell disease patients.
Nigeriaalpha thalassemia · drépanocytosepublished 2022Mediterranean journal of hematology and infectious diseaseseurope_pmcdocument of 17 observationsDOI 10.4084/mjhid.2022.001
13.2 %In the study, 13.2% of children with sickle cell anaemia had proteinuria.
Nigeriadrépanocytosepublished 2024West African journal of medicinePubMeddocument of 9 observations
12.7 %Cholelithiasis was observed in 12.7% of the children.
Nigeriacholelithiasis · drépanocytosepublished 2021West African journal of medicinePubMeddocument of 10 observations
46 %In the phase 2 portion of the RISE UP trial, the haemoglobin response rate (≥1.0 g/dL increase from baseline in average haemoglobin concentration from week 10 through week 12) was 46% in the mitapivat 50 mg group.
Nigeriadrépanocytosepublished 2025The Lancet. Haematologyeurope_pmcdocument of 9 observations
A significant high proportion of children with sickle cell anemia had abnormal valvar dimension and left ventricular function above two standard deviations from the mean of the standard population compared to the control group.
Nigeriadrépanocytosepublished 2021Malawi medical journal : the journal of Medical Association of MalawiPubMeddocument of 3 observations
80 %Among 308 children with sickle cell disease in Nigeria, cerebral artery blood velocity was normal in 246 (80%), high in 14 (4.5%), and conditional in 48 (15.5%).
Nigeriadrépanocytosepublished 2023Archives of disease in childhoodPubMeddocument of 5 observations
70 %Sickle cell disease is one of the most common haemoglobinopathies worldwide, with up to 70% of global SCD annual births occurring in sub-Saharan Africa.
Nigeriadrépanocytosepublished 2022Current stem cell research & therapyeurope_pmcdocument of 2 observations
10.9 %Stunting was observed in 10.9% of subjects with sickle cell anemia.
Nigeriadrépanocytose · malnutritionpublished 2020Nigerian journal of clinical practicePubMeddocument of 9 observations
21.1 %Among 133 children with sickle cell disease, 28 (21.1%) had documented neurological manifestations.
Nigeriadrépanocytoseobserved March 2022 and February 2025PubMeddocument of 8 observations
62.5 %More than half (62.5%) of the participants had SCD crisis within six months.
Nigeriadrépanocytoseobserved six monthspublished 2020The Pan African medical journalPubMeddocument of 8 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.